interferon

(redirected from interferon alfa-2a)
Also found in: Dictionary, Thesaurus, Medical.
Related to interferon alfa-2a: interferon alfa-2b, Roferon

interferon

(ĭn'tərfēr`ŏn), any of a group of proteins produced by cells in the body in response to an attack by a virusvirus,
parasite with a noncellular structure composed mainly of nucleic acid within a protein coat. Most viruses are too small (100–2,000 Angstrom units) to be seen with the light microscope and thus must be studied by electron microscopes.
..... Click the link for more information.
. A cell infected by a virus releases minute amounts of interferons, which attach themselves to neighboring cells, prompting them to start producing their own protective antiviral enzymes. The result is impairment of the growth and replication of the attacking virus. Interferon has also been shown to have some antitumor properties. There are three known classes of interferons: alpha-, beta-, and gamma-interferons.

Although they were discovered in the 1950s, the medical use of interferons was impractical until the recombinant DNA techniques of genetic engineeringgenetic engineering,
the use of various methods to manipulate the DNA (genetic material) of cells to change hereditary traits or produce biological products. The techniques include the use of hybridomas (hybrids of rapidly multiplying cancer cells and of cells that make a
..... Click the link for more information.
 made it possible to mass produce them. Interferons used as drugs include alpha-interferon, for hepatitishepatitis
, inflammation of the liver. There are many types of hepatitis. Causes include viruses, toxic chemicals, alcohol consumption, parasites and bacteria, and certain drugs.
..... Click the link for more information.
 B and C, human papillomavirushuman papillomavirus
(HPV), any of a family of more than 100 viruses that cause various growths, including plantar warts and genital warts, a sexually transmitted disease. Genital warts, sometimes called condylomata acuminata, are soft and often occur in clusters.
..... Click the link for more information.
, hairy-cell leukemialeukemia
, cancerous disorder of the blood-forming tissues (bone marrow, lymphatics, liver, spleen) characterized by excessive production of immature or mature leukocytes (white blood cells; see blood) and consequently a crowding-out of red blood cells and platelets.
..... Click the link for more information.
, and Kaposi's sarcomaKaposi's sarcoma
, a usually fatal cancer that was considered rare until its appearance in AIDS patients. First described by an Austro-Hungarian physician, Moritz Kaposi, in 1872, it appears in three forms and is characterized by vascular skin tumors.
..... Click the link for more information.
 (a cancer associated with AIDSAIDS
or acquired immunodeficiency syndrome,
fatal disease caused by a rapidly mutating retrovirus that attacks the immune system and leaves the victim vulnerable to infections, malignancies, and neurological disorders. It was first recognized as a disease in 1981.
..... Click the link for more information.
), and beta-interferon, for multiple sclerosismultiple sclerosis
(MS), chronic, slowly progressive autoimmune disease in which the body's immune system attacks the protective myelin sheaths that surround the nerve cells of the brain and spinal cord (a process called demyelination), resulting in damaged areas that are unable
..... Click the link for more information.
.

See also immunityimmunity,
ability of an organism to resist disease by identifying and destroying foreign substances or organisms. Although all animals have some immune capabilities, little is known about nonmammalian immunity.
..... Click the link for more information.
.

The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Interferon

 

a protective protein manufactured by cells in mammals and birds and by cell cultures in response to their infection by viruses, suppressing the reproduction (replication) of the viruses in the cells.

Interferon was discovered in 1957 in the cells of infected chickens by the English scientists A. Isaacs and J. Lindenman. It was later discovered that the formation of interferon is also induced by bacteria, rickettsia, toxins, nucleic acids, and synthetic polynucleotides. Interferon is not an individual substance but a group of proteins of low molecular weight (25,000110,000). They are stable within a wide pH range, resistant to nucleases, and destroyed by proteolytic enzymes. The formation of interferon in the cells is due to the development of a virus in them—that is, it is a reaction of the cells to the penetration of foreign nucleic acid. Interferon is not found after the disappearance of the infecting virus from the cells or in normal cells. The mechanism of interferon’s action is different in principle from that of antibodies: it is not specific in relation to viral infections (it is active against a variety of viruses), and it does not neutralize the infectiousness of the virus, but suppresses the reproduction of the virus in the body by inhibiting the synthesis of the viral nucleic acids. Interferon is ineffective when it enters cells after a viral infection has already developed in them. Moreover, interferon is, as a rule, specific for the cells that form it; for example, the interferon of chicken cells is active in those cells only and does not inhibit the reproduction of a virus in rabbit or human cells. It has been suggested that it is not interferon itself that acts on the viruses, but rather another protein that is produced under its influence. Encouraging results have been obtained in testing interferon for the prevention and treatment of viral diseases (herpes infection of the eyes, influenza, cytomegaly). However, broad clinical use of interferon is limited by the difficulty of obtaining the preparation, the necessity for multiple injections, and its species specificity.

REFERENCES

Solov’ev, V. D., and T. A. Bektimirov. Interferon v teorii i praktike meditsiny. Moscow, 1970.
Isaacs, A., and J. Lindenmann. “Virus Interference. I: The Interferon.” Proceedings of the Royal Society of London, series B:Biological Sciences, 1957, vol. 147, no. 927.
Vilček, I. Interferon. Vienna-New York, 1969.

KH. KH. PLANEL’ES

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.

interferon

[‚in·tər′fir‚än]
(biochemistry)
A protein produced by intact animal cells when infected with viruses; acts to inhibit viral reproduction and to induce resistance in host cells.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.

interferon

Biochem any of a family of proteins made by cells in response to virus infection that prevent the growth of the virus. Some interferons can prevent cell growth and have been tested for use in cancer therapy
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005
References in periodicals archive ?
Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1.
A randomized trial comparing pegylated interferon alfa-2b to pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in renal-cell carcinoma.
A combination therapy involving use of a pegylated (long-acting) form of interferon alfa-2a and ribavirin, for chronic hepatitis C (HCV) in adults not previously treated with interferon-[alpha].
WASHINGTON -- Interferon alfa-2a can be used to treat infants with aggressive hemangiomas without the associated neurotoxicity by avoiding preparations using benzyl alcohol, Dr.
BOSTON - Adding pegylated interferon alfa-2a to entecavir increased the chance of long-term viral suppression of chronic hepatitis 13 infections in a randomized trial of 160 patients.
Discoverer and developer of small molecule drugs Achillion Pharmaceuticals Inc (Nasdaq:ACHN) on Saturday announced that in the second segment of its Phase 2a trial of ACH-1625, 94% to 100% of patients with treatment naive genotype 1 chronic hepatitis C virus (HCV) achieved a complete early virologic response (cEVR) after 12 weeks of treatment with ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R).
This Phase IIa, randomised, double-blind, placebo-controlled trial will evaluate the safety, tolerability and antiviral activity of oral ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin after 28 days of dosing and after 12 weeks of dosing in subjects with chronic hepatitis C virus genotype 1.
During the course of this pilot clinical trial, patients will receive 12 months of triple therapy of a standard dose of ZADAXIN (1.6 mg/bi-weekly) plus a standard dose of pegylated interferon alfa-2a (180 mcg/week) and a low dose of ribavirin (800-1,000 mg/day) and will be observed for six months after completing therapy to measure sustained response.
Since 2006, when the innovator obtained the first product patent (incidentally, the patent was also the first of its kind after India started honoring product patents in 2005) for pegylated interferon alfa-2a (Pegasys), the company has involved in at least a dozen patent infringement disputes in Indian courts.
The first study is designed to provide clinical data on the use of VICTRELIS (boceprevir), an oral HCV NS3/4A protease inhibitor, in combination with mericitabine (RO5024048), Roche's investigational oral HCV NS5B nucleoside polymerase inhibitor, Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin), in adult patients with chronic HCV genotype 1 infection who had a null response to prior peginterferon alfa and ribavirin therapy (less than a 2 log HCV-RNA decline at treatment week 12).